SonoVol Awarded Phase 1 National Cancer Institute SBIR Grant

NCI_LogoSonoVol is pleased to announce the receipt of a National Institutes of Health – National Cancer Institute SBIR award: “Development of an ultrasound-optical hybrid modality preclinical imaging tool.” This award will infuse over $200,000 in non-dilutive capital into the company’s product development engine.

The yearlong research and development effort is underway, and will result in the necessary hardware and software components to prove feasibility of a multi-modality SonoVol system. This device will combine the fastest and least expensive modalities from each class of imaging (anatomical and functional) when low cost high throughput ultrasound images are fused with functional optical images.

In the future, this benchtop hybrid-modality device should help reduce the cost and increase the pace of preclinical drug studies in both academic and industry settings by providing cheaper hardware and increased throughput.